Immunoprotective influenza antigen and its use in vaccination
AssigneeVlaams Interuniversitair Instituut Voor Biotechnolgoie
InventorsSabine Neirynck, Willy Min Jou, Walter Fiers
Life of this patent
Estimating the term…
Abstract
The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.
Claims14
A method to reduce morbidity from a human influenza A infection comprising the step of administering to a person at risk of such infection, in an amount effective for reducing morbidity, a composition comprising a fusion product, said fusion product comprising
- (i) an antigen comprising an immunogenic extracellular part of an M2 membrane protein of a human influenza A virus, wherein said extracellular immunogenic part of an M2 protein consists of SEQ ID NOs:
- 1, 2 or 3, or an immunogenic fragment thereof that induces antibodies to human influenza A virus, and
- (ii) a heterologous presenting carrier.
A method to reduce morbidity from a non-human influenza infection comprising the step of administering to a non-human animal at risk of such infection, in an amount effective for reducing morbidity, a composition comprising a fusion product, said fusion product comprising
- (i) an antigen comprising an immunogenic extracellular part of an M2 membrane protein of an influenza A virus, wherein said extracellular part of an M2 protein consists of SEQ ID NOs:
- 1, 2 or 3, or an immunogenic fragment thereof that induces antibodies to human influenza A virus, and
- (ii) a heterologous presenting carrier.
Dependencies are inferred from the claim text.